Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has agreed to acquire 35Pharma Inc., a Canada-based clinical-stage biopharmaceutical company, for USD950m in cash, expanding its respiratory and immunology pipeline.

The acquisition includes HS235, an investigational activin signalling inhibitor that has completed phase I trials and is set to enter studies in pulmonary arterial hypertension and pulmonary hypertension linked to heart failure. The therapy is designed to improve selectivity and reduce binding associated with adverse events, including bleeding, potentially addressing key limitations in existing treatments.

Pulmonary hypertension is a progressive disease affecting approximately 82 million people globally, with a five-year survival rate of around 50% and limited treatment options. The global market for therapies is projected to reach USD18bn by 2032, with activin signalling inhibitors expected to account for a significant share.

HS235 may also deliver metabolic benefits, including fat-selective weight loss, preservation of lean mass and improved insulin sensitivity, supporting its potential differentiation in a patient population with high rates of obesity and insulin resistance.

GSK said the asset strengthens its emerging portfolio of therapies targeting metabolic and vascular function within its Respiratory, Immunology and Inflammation business. The transaction remains subject to regulatory approvals in the United States and Canada.